Evolution of the development of PARP inhibitors -- Exploiting cancer synthetic lethality in cancer - Lessons learnt from PARP inhibitors -- Mechanisms of PARP inhibitor resistance -- Development of homologous recombination functional assays for targeting the DDR -- Clinical application of Poly(ADP Ribose) Polymerase (PARP) inhibitors in ovarian cancer -- Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer -- Development of PARP inhibitors in targeting castration-resistant prostate cancer -- Strategies for the management of patients with pancreatic cancer with PARP inhibitors -- Combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: Promise and challenges -- Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents -- Combining PARP inhibition and immunotherapy in BRCA-associated cancers -- Mitotic MTH1 inhibitors in treatment of cancer -- Targeting ATR in cancer medicine -- Targeting polymerase Theta (POLq) for cancer therapy -- Targeting DNA-PK -- WRN is a promising synthetic lethal target for cancers with microsatellite instability (MSI).